Cargando…

A Rare, Yet Treatable Pancreatic Tumor: Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma

Patient: Male, 62-year-old Final Diagnosis: Pancreatic lymphoma Symptoms: Epigastric pain • unintentional weight loss Medication: — Clinical Procedure: — Specialty: Oncology OBJECTIVE: Rare disease BACKGROUND: Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) is a rare subtype...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, John, Rinker, Elizabeth, Zaarour, Mazen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101472/
https://www.ncbi.nlm.nih.gov/pubmed/32176677
http://dx.doi.org/10.12659/AJCR.921269
Descripción
Sumario:Patient: Male, 62-year-old Final Diagnosis: Pancreatic lymphoma Symptoms: Epigastric pain • unintentional weight loss Medication: — Clinical Procedure: — Specialty: Oncology OBJECTIVE: Rare disease BACKGROUND: Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) is a rare subtype of B-cell neoplasm that can have diverse presentations. When it involves the pancreas (i.e., pancreatic lymphoma), it can mimic metastatic pancreatic adenocarcinoma. Pancreatic lymphoma and adenocarcinoma often have similar clinical, laboratory, and radiographic features making the distinction challenging without pathological tissue examination. The differentiation of these 2 entities is important as the prognosis of pancreatic lymphoma is certainly more favorable with a chance of cure with chemoimmunotherapy. CASE REPORT: We present an unusual case of EBV-positive DLBCL involving the pancreas that was initially believed to be metastatic pancreatic adenocarcinoma. The patient was treated with chemoimmunotherapy and had a remarkable response. This is the first known case of EBV-positive DLBCL involving the pancreas that was successfully treated with chemoimmunotherapy. CONCLUSIONS: EBV-positive DLBCL can have diverse presentations, including a pancreatic mass with multi-organ involvement, which mimics metastatic pancreatic adenocarcinoma. The prognosis of EBV-positive DLBCL is thought to be worse than that of EBV-negative tumors. However, it remains certainly superior to that of its adenocarcinoma counterpart with conventional chemoimmunotherapy.